Description
ADLINA EM 25/5 mg is an oral antidiabetic combination tablet containing Empagliflozin 25 mg and Linagliptin 5 mg. This once-daily, dual-action formulation provides complementary glucose-lowering mechanisms to help patients with type 2 diabetes achieve better glycemic control.
-
Empagliflozin promotes urinary glucose excretion by inhibiting the SGLT2 transporter in the kidneys.
-
Linagliptin enhances incretin activity, stimulating insulin release and reducing glucagon in a glucose-dependent manner.
Together, they help reduce fasting and postprandial blood glucose, with added benefits of weight loss, low hypoglycemia risk, and cardiovascular/renal protection.
 40 ML.png)
 250 ML.jpeg)
60 ML 60 ML.webp)
 30 TAB.webp)
 15ML.webp)
 200 ML.jpeg)
 200ML.jpg)
 20ML.jpeg)
.webp)
 150GM.webp)
.webp)
 200ML.webp)
 50ML.webp)
 100ML.png)
 125ML.jpg)
 200ML.webp)
 125ML.webp)
Change Language